Home/Pipeline/Preclinical ISAC 1

Preclinical ISAC 1

Undisclosed

PreclinicalAvailable for Partnering

Key Facts

Indication

Undisclosed

Phase

Preclinical

Status

Available for Partnering

Company

Bolt Biotherapeutics

About Bolt Biotherapeutics

Bolt Biotherapeutics is developing targeted immunotherapies based on its proprietary Boltbody™ Immune-Stimulating Antibody Conjugate (ISAC) platform, which aims to harness the innate immune system to fight cancer. Founded in 2015 on foundational research from Stanford University, the company's strategy centers on advancing its lead clinical asset, BDC-4182, and leveraging collaborations to expand its pipeline. As a pre-revenue public company, Bolt faces the critical challenge of generating compelling clinical proof-of-concept data to validate its platform and attract further investment or partnership capital in a competitive oncology landscape.

View full company profile

Therapeutic Areas

Oncology

Other Undisclosed Drugs

Drug	Company	Phase	Status
Preclinical ISAC 2	Bolt Biotherapeutics	Preclinical	Available for Partnering
ART12.11	Artelo Biosciences	Preclinical	Active
Novel Vaccines	MSD	Development	Active
SLS-009	Seelos Therapeutics	Discovery	Research
Measovir®-based Prophylactic Vaccine (with Unither)	Oncovita	Research/Pre-clinical	Early-stage collaboration
Internal sdAb Discovery Program	NanoTag Biotechnologies	Discovery	Active
Amgen Collaboration Program	Xeris Biopharma	Pre-clinical	Active
NB-701	Nerai Biosciences	Discovery	Active
Undisclosed Therapeutic Program(s)	Bright Cell	Clinical Trial (Phase unspecified)	Active
Biosimilars Pipeline	Intelligent Therapeutics	Pre-clinical/Development	Active
Proprietary Therapeutic Pipeline	Excelsior Sciences	Discovery	Active
Therapeutic Programs	Agathos Biologics	Pre-clinical	Active